On October 8, 2026, Editas Medicine, Inc. announced via a Form 8-K filing that it has obtained approval to commence the Phase 1/2 Strive clinical trial of EDIT-401 targeting patients with heterozygous ...
On October 14, 2026, Entrada Therapeutics, Inc. submitted a Form 8-K revealing topline results from Cohort 1 of its Phase 1/2 ELEVATE-45-201 clinical trial evaluating ENTR-601-45 in ambulatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results